

## THE PROBLEM

### +150,000

Transplants per year in the world and 65% are renal



### **50%**

Of kidney transplant patients, 10% die within 10 years due to ineffective treatments with immunosuppressants that inhibit the activity of the entire immune system to prevent rejection of transplanted organs.


# **OUR SOLUTION**

Specific cellular therapy based on

Tregs

Inhibits the immune response to transplantation

Organ and tissue rejection. Autoimmunity. Inflammation.



Market for immunosuppressive drugs in patients with kidney transplants

### **FOUNDING TEAM**

Pre-Gotomarket




**Gloria Soldevila, PhD** Founding researcher Titular C (25 years UNAM)



Arimelek Cortés, PhD

Co-founder, Inventor



The patient's

Treg cells are

"educated" to

specifically

compress

**Evelyn Álvarez Salazar, PhD** Co-founder, Inventor



Inmune balance for health

3



**Roxana Olguín Alor, PhD** Co-founder Quality management



#### **Scientific advisors**



**Joaquim Vives, PhD** Banc de Sang i Teixits of Catalunya, Barcelona España





8



**Saúl Arteaga, PhD** Co-founder, Inventor Buenrostro, M.D. INCMN Salvador Te Zubirán Mexico

**Josefina Alberú, PhD** Tec Monterrey Mexico

### INVESMENT

# Stage 1 Fundraising USD 1,836,450 millions

Funding to complete the preclinical phase and obtain permission to start the clinical phase



Specialized advice and regulatory expenses

Working capital (OPEX)

USD 243,500 (13.5%)

**USD 139,450** (7.5%)

#### In the next 18 months

Scaling up cell production (54%)



Cofepris approval (7%)

**Contact:** 

Francisco Lozano Martínez flozano@newgenesis.cl

Raúl Vázquez Cassani rvazquez@newgenesis.cl

